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Takayasu’s arteritis is a rare chronic vasculitis of unknown etiology. Symptomatic pulmonary artery
disease may be the ﬁrst sign of Takayasu’s arteritis. We describe a 51-year-old woman who presented
with severe dyspnea. The initial evaluation and routine exams suggested the presence of pulmonary
hypertension of unknown etiology. Absence of bilateral radial and brachial pulses in the physical
examination led to an angiographic study, which conﬁrmed the diagnosis of Takayasu’s arteritis with
severe pulmonary hypertension. During bosentan therapy, the patient’s clinical symptoms and exercise
capacity improved and her 6-min walking distance increased. We emphasize the importance of
considering Takayasu’s arteritis in the early diagnosis and therapy of pulmonary artery hypertension.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Takayasu’s arteritis (TA) is a chronic idiopathic vasculitis that
mainly affects the aorta and/or its main branches and, to a lesser
extent, the pulmonary arteries.1 The incidence of Takayasu’s
arteritis is about 2/10,000 person-years, with a tenfold predomi-
nance in women, especially those under 40 years of age.2 Clinical
presentationmay be insidious, and diagnosis is often delayed. Signs
of pulmonary artery involvement as the initial predominant clinical
manifestation are rare. Here, we present a case of Takayasu’s
arteritis that presented with symptoms and signs of pulmonary
hypertension. This case report highlights the importance of differ-
ential diagnoses and the importance of modern-day imaging in
diagnosis.2. Case report
A 51-year-old female was referred to our hospital because of
progressive dyspnea. A slight dyspnea on exertion appeared 4 years
ago and deteriorated within the last 3–4 months, leading to
shortness of breath at low physical activity levels. There were no
associated symptoms such as orthopnea, paroxysmal nocturnal
dyspnea, hemoptysis or cough. A year previously, a coronary
angiography had been performed in another hospital, where this
showed normal coronary arteries. At that time, her right and left
brachial and radial pulses were absent. Aortography demonstrated1.
tu¨rk).
rved.stenosis of both the right and left subclavian arteries; warfarin
therapy was started after this discovery. Upon physical examina-
tion, bilateral brachial and radial artery pulses were absent; as
a result, blood pressure from the right and left upper extremities
could not be measured. The patient’s femoral pulses were present.
The laboratory ﬁndings only showed a slightly elevated erythrocyte
sedimentation rate (ESR: 48 mm/h) and an increased C-reactive
protein level (CRP: 5.16 mg/dl); the patient’s differential blood
count was normal. The initial electrocardiography (ECG) showed
right ventricular hypertrophy and right axis deviation. The chest
radiograph and lung function tests were normal. Rheumatoid
factor, antinuclear antibodies, anti-DNA antibody, anti-neutrophil
cytoplasmic antibody, viral serology and anti-CCP were all negative.
On admission, the patient was in the New York Heart Association
(NYHA) functional class III, with a 6-min walk distance of 160 m.
The patient’s echocardiography showed an ejection fraction of
72%, right ventricular enlargement with paradoxical septal motion,
right atrial enlargement, severe tricuspid regurgitation and
95 mmHg maximal pulmonary artery pressure. Pulmonary hyper-
tension due to thromboembolismwas considered in the differential
diagnosis, so a computed tomography of the chest was performed.
The results showed that the right pulmonary artery was no longer
visible from its origin (Fig. 1). The diameter of the main pulmonary
artery was increased (35 mm). There was no ﬁnding of pulmonary
embolism. A ventilation–perfusion scan revealed normal ventila-
tion in both lungs but a near-total perfusion defect in the right lung.
Low extremity vascular evaluation by Doppler ultrasonography
showed no abnormality. Intra-arterial digital subtraction angiog-
raphy revealed that the right subclavian artery after the origin of
the right vertebral artery was completely occluded as the distal part
Fig. 1. Thorax CT showing complete occlusion of the right pulmonary artery (arrows).
Fig. 2. Digital subtraction angiography revealing total occlusion of the right and left
subclavian arteries (arrows).
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ography scan of the abdomen showed normal abdominal aorta,
renal arteries and celiac trunk. Consequently, a coronary angiogram
was performed, which showed normal coronary arteries. A mean
pulmonary artery pressure of 50 mmHg and a pulmonary artery
wedge pressure of 10 mmHg were found after performing a right
heart catheterization.
We diagnosed the patient as having Takayasu’s arteritis based
on the following ﬁndings, which fulﬁlled the American College of
Rheumatology 1990 criteria3: decreased brachial artery pulse, pulse
pressure difference of more than 10 mmHg between the two upper
extremities and angiography ﬁndings.
Other differential diagnoses that were considered and excluded
were Wegener’s granulomatosis, giant cell arteritis, Behçet’s
disease, sarcoidosis, neoplastic disorders and systemic infectious
diseases. The illness of patient was in the chronic phase; therefore,
no immunosuppressive therapy was started. Due to the high risk of
arterial thromboembolism, warfarin therapy was continued.
Additionally, the patient was treated with bosentan 125 mg/day.
After 6 months of bosentan treatment, the patient’s clinical
symptoms had improved signiﬁcantly: her 6-min walk distance
increased to 255 m and she improved rapidly to NYHA class II; in
addition, transthoracic echocardiography showed that there was
a decrease in pulmonary artery pressure.3. Discussion
In this study, we report a case of Takayasu’s arteritis with
pulmonary artery involvement. Takayasu’s arteritis, a chronic
inﬂammatory arterial disease of unknown cause, occurs predomi-
nantly in young women.4 After reviewing the literature and
speciﬁcally searching for pulmonary artery involvement, it was
found in an average of 56% of the cases studied.5 A few reported
cases of patients with Takayasu’s arteritis complained of symptoms
of pulmonary hypertension.6–8 Our patient demonstrated atypical
manifestations of Takayasu’s arteritis, which are typically associ-
ated with pulmonary artery involvement and pulmonary artery
hypertension. The increasing breathlessness noted during the 4
months prior to admission is probably related to progressive
pulmonary hypertension. It is difﬁcult to distinguish these cases
from primary lung disease and chronic pulmonary embolism. The
patient had no signs of acute pulmonary embolism or history of
vein thrombosis. In the absence of systemic involvement, thedifferential diagnosis between Takayasu’s arteritis and chronic
thromboembolic disease may be facilitated by an accelerated ESR,
but as was the case for our patient, a normal ESR cannot rule out
a diagnosis of Takayasu’s arteritis. Other diagnoses, including
primary pulmonary hypertension, ﬁbrosing mediastinitis and
congenital stenosis of the pulmonary artery and tuberculosis, were
suspected based on the initial clinical presentation. In the case of
large vessel involvement, temporal arteritis and anti-phospholipid
syndrome should be considered in the differential diagnosis.
However, temporal arteritis was unlikely since the patient did not
suffer from headache and her temporal artery pulsation was
normal. A diagnosis of anti-phospholipid syndrome seemed
unlikely since antinuclear antibody and anti-cardiolipin antibody
assays were negative and the patient did not have a history of
abortus. In our case, CT and MRI were decisive in diagnosing
Takayasu’s arteritis. In the literature, the interval between the onset
of symptoms and diagnosis of Takayasu’s arteritis ranges from 1 to
16 years.6,7 Our patient was 51-year-old woman. Total occlusion of
left pulmonary artery and symptoms and signs related to its
involvement were very late manifestations in the present case. The
most characteristic ﬁndings of pulmonary artery involvement
in Takayasu’s arteritis are stenosis or occlusion, mainly of
the segmental and subsegmental arteries and less commonly of the
lobar or main pulmonary arteries.1 Unilateral total occlusion of
the right or left pulmonary artery is very rare and can occur in
advanced and late-phase disease.9 In the present case, chest CT
ﬁndings were consistent with pulmonary artery involvement, and
our patient had total occlusion of the left pulmonary artery.
Our patient had severe pulmonary hypertension accompanied
by severe symptoms. Since pulmonary artery stenosis develops
chronically, most patients only show signs of mild-to-moderate
pulmonary hypertension. Lupi et al. retrospectively analyzed 22
patients with Takayasu’s disease and found that 50% of the cases
had pulmonary involvement.10 No patients had pulmonary symp-
toms, but 63% had clinical, radiological and electrocardiographic
ﬁndings suggesting pulmonary hypertension or right heart strain.
We also ruled out chronic pulmonary emboli by chest CT and
ventilation–perfusion scan. The patient was started on oral
warfarin and intravenous heparin concurrently. After the PT
reached therapeutic levels with an INR between 2 and 3, heparin
treatment was discontinued.
ET-1 is a potent endogenous vasoconstrictor and a mitogen for
ﬁbroblasts, smooth muscle and endothelial cells.11 The endothelin
(ET) system, especially ET-1 and the ETA and ETB receptors, has
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tension (PAH), as plasma ET-1 levels are elevated in patients with
PAH and Takayasu’s disease.12 Bosentan shows an almost equal
afﬁnity for both receptors, with an ETA: ETB afﬁnity ratio of 40:1.
Bosentan is thus commonly referred to as a dual endothelin
receptor blocker.13 Following its approval by the US Food and Drug
administration (FDA) in 2001, bosentan is now available in many
parts of the world. For patients who have no positive acute vaso-
dilator testing and are considered to be less risky based on clinical
assessment, oral therapy with an endothelin receptor blocker
would be the ﬁrst line of therapy recommended. Bosentan has been
approved for the treatment of WHO-FC II and III patients.14 The
mechanism is thought to involve inhibition of vasoconstriction, cell
hyperplasia and hypertrophy and an increase in the extracellular
matrix. Our patient was considered to have PAH associated with
Takayasu’s disease. Bosentan treatment was started at a dose of
62.5 mg twice daily, which was increased to 125 mg twice daily
after 4 weeks. Six months after starting 62.5 mg twice-daily
bosentan, the patient’s clinical symptoms had improved signiﬁ-
cantly, and echocardiography revealed a reduction in mean PAP.
In conclusion, this case report demonstrated that symptoms
arising from pulmonary hypertension in Takayasu’s arteritis may
exist. The diagnosis of Takayasu’s arteritis is often mistaken for
a different pathological diagnosis, depending of the signs and
symptoms at a particular time. Takayasu’s arteritis should be
considered in the presence of pulmonary hypertension of unknown
etiology. Our interesting case suggests that the endothelin receptor
blocker bosentanmay provide an effective solution to attenuate the
PAH in Takayasu’s disease.Conﬂict of interest
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